Supernus Pharmaceuticals and Indivior Pharmaceuticals have entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction to create a leading diversified, central nervous system (CNS) biopharmaceutical company.  The companies expect the transaction to generate significant value for stockholders of both companies, realising $125 million in expected annual cost synergies.   The […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!